FGF2 and ischemic cardiomyopathy: In the same year, another phase I trial called ALCADIA (AutoLogous human CArdiac-Derived stem cell to treat Ischemic cArdiomyopathy) used autologous human CPCs in combination with a controlled released of bFGF in patients suffering from ischemic cardiomyopathy and heart failure [284,285].